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1. Introduction 
Gliomas are the most frequent primary brain tumors and are classified as grade I to IV 
according to their degree of malignancy (Daumas-Duport et al., 1988). Grade I and II 
gliomas are clinically benign or semi-benign with relatively long-term survival, while grade 
III and IV are malignant and lethal within several years. In particular, glioblastoma 
multiforme (GBM), the most malignant glioma as grade IV often relapse even after radical 
surgical resection and standard chemo/radiation therapies, because of their diffuse 
infiltration into the surrounding brain parenchyma and high degree of 
chemo/radioresistance. Despite extensive efforts, the overall survival of GBM patients 
remains still short and has not yet been dramatically improved for more than several 
decades. 
GBMs are often composed of various types of cells with distinct morphology and clinical 
phenotypes. Their histological and biological multiformity has been classically explained by 
the stochastic clonal evolution model (Nowell, 1976). According to this model, all tumor 
cells should have low but inheritable ability to form tumors. However, recent evidence has 
suggested another concept, the cancer stem cell (CSC) hierarchy model, which shows that 
only a rare stem cell population has high ability to proliferate (Jordan et al., 2006). CSCs 
have similar characters to normal stem cells in the way of having high ability to self-renew 
and differentiate into multiple types of progenies to organize tissue architectures. 
Exclusively, CSCs can proliferate uncontrollably to propagate tumor cells. CSC model have 
direct relevance with tumor replenishment, disease recurrence and metastatic activity, 
suggesting that CSCs should be the target to eradicate the tumors.  
The aim of this chapter is to provide our insights into how CSCs in human glioma; i.e. 
glioma stem cells (GSCs) should be attacked. In the first parts, we summarize the general 
basis of CSC concept inclusive of the current knowledge on how a CSC is defined, how 
CSCs should be technically prepared and modeled, and what characteristics CSCs possess. 
In the following part, we highlight what abnormal signaling pathways regulate CSCs as the 
potential therapeutic targets. Understanding the framework of a GSC research field could 
help us to think of novel treatment strategy. Most importantly, however, CSCs have 
enhanced resistance to conventional chemotherapies. Considering this fact, we finally 
propose that it could be most promising strategy to disrupt the extracellular environments 
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supporting GSCs, which is a newly emerging concept “niche therapy”. We present possible 
cellular and molecular components of GSC niche and discuss their potentiality as innovative 
therapeutic targets. 
2. General outlines of cancer stem cell 
2.1 Heterogeniety of cancer tissue 
Over the past several decades, the idea that cancer tissues are heterogeneous and composed 
of multiple subpopulation of cells differing in morphology, proliferation rate, metastatic 
potential, marker expression, and sensitivity to chemo/radiation therapies, has been highly 
appreciated by many investigators. This tumor heterogeneity has been classically explained 
by the following two models (Figure 1). 
Clonal evolution (stochastic) model: Cells may acquire various combinations of genetic and 
epigenetic mutations asynchronously and once such mutations confer selective advantages 
of tumor malignancy, more aggressive and adaptive clones can dominate the whole tumor 
population. 
In 1976, Nowell proposed the evolutionary view into tumor progression as a stochastic 
process of genetic instability and natural selection (Nowell, 1976). According to this model, 
tumor initiation occurs in the individual cells receiving multiple mutations, and cells having 
an advantageous mutation of growth can clonally proliferate and selectively occupy an 
entire tumor. During tumor progression, genetic instability yields the additional mutations 
by chance, resulting in a diversity of genome and cell characteristics, such as being invasive, 
metastatic and therapy-resistant. The adaptation to surrounding microenvironment is also a 
determinant of the selection. Standing on this concept, all the tumor cells should have low 
but inheritable ability to form tumors, therefore, the rational targets for cancer therapy is 
most or all of tumor cells. After this proposal, researchers have confirmed clonal expansions 
and genetic heterogeneity within various types of human neoplasms. 
Hierarchy (cancer stem cell) model: Cells may acquire various genetic and epigenetic 
mutations that confer stem-like characteristics, and divide to produce its identical copy (self-
renewal) and progenies terminally growth-arrested (differentiation). Such a hierarchy in a 
stem cell division manner results in cellular diversity of a rare stem cell and a majority of 
multiple types of progenies. 
The CSC model is not a newly emerging concept indeed. The efforts to gain insights into 
tumor’s malignant potential, especially their differential sensitivity to anticancer drugs were 
made on this concept with specimens from patients with myeloma and with ovarian cancer 
(Salmon et al., 1978). The technological advances of flow cytometry and discovery of stem 
cell surface antigens accelerated investigators to ascertain this concept, starting in human 
leukaemia (Bonnet and Dick, 1997) along with the subsequent identification in breast (Al-
Hajj et al., 2003) and brain tumor (Singh et al., 2003). 
Normal stem cells replenish normal tissues by fresh cells continuously throughout life in 
individual organs. Stem cells are characterized by two main hallmarks; those are 
multipotency and self-renewal capacity. The former is the ability to produce multiple types 
of functional progenies, which is associated with terminal growth-arrest. Self-renewal is the 
ability to produce new stem cells identical to original one with retaining the intact two main 
hallmarks, and thereby maintains the stem cell pool. Likewise, tumors are also organized as 
a hierarchy where rare CSCs stand at the top of pyramid with extensive potential to 
proliferate and self-renew and are responsible for maintaining the homeostasis of the tumor 
bulk, except that CSCs disorderly propagate tumor cells and increase cell number. 
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Fig. 1. The color of the arrow for 2nd mutation in Hierarchy model is changed from pale 
yellow to light blue.  
In this concept, cancer heterogeneity means the different characteristics between CSC and 
differentiated cancer progenies. However, the clonal evolution model and the CSC model 
are not necessarily mutually exclusive. Despite types of primary cells to suffering the first 
set of mutations, CSCs also have genetic instability, which increases the probability of 
acquiring additional mutations. Potentially, CSCs might expand clonally by a symmetric 
division. The adaptation to surrounding microenvironment has also been recognized as 
important factors on normal stem cell maintenance, which is called stem cell niche. 
Therefore, we should consider the CSC model as a revised version by taking the idea of 
asymmetric division. However, we must note again that only rare CSCs are tumorigenic by 
definition and specific targets for cancer eradication is in a minority population within a 
tumor bulk. 
2.2 Definition of cancer stem cell 
CSCs are re-defined in the AACR Workshop 2006 on Cancer Stem Cells as “a small subset of 
malignant cells that constitute a pool of self-sustaining cells with the exclusive ability to 
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maintain the tumor” (Clarke et al., 2006), and in part share the fundamental properties with 
normal stem cells specific to their original organs; e.g. neural stem cell for glioma. 
2.3 Current methods to isolate cancer stem cell 
In current studies, CSCs from cancer tissues and cell lines are firstly isolated by using 
diverse experimental techniques as mentioned below. 
Sphere formation assay: Floating spherical cell clusters are formed in vitro when mitotic 
cells are cultured in serum-free media supplemented with mitogens (epidermal growth 
factor and fibroblast growth factor for neural stem cells) (Figure 2), which is originally 
developed to characterize the behaviour of neural stem cells (Reynolds and Weiss, 1992). 
 
A B
 
Fig. 2. Glioma spheres generated from oncogenic Ras-transformed human astrocytes (A) and 
differentiation of dissociated sphere cells by culturing in 10%FBS media for 1 week (B). 
When cells are derived from brain, breast and others, each sphere is called neurosphere, 
mammosphere, and others, respectively. The number and diameter of spheres are thought 
to reflect the frequency of stem cells and mitotic activity of a single stem cell within the 
examined population, respectively. When a 1st sphere is picked up, re-dissociated into 
single cells, and re-cultured, the generated secondary spheres imply the sustained self-
renewal potential of a true stem cell. For a while, this method has been utilized to expand 
cancer stem cell population by serial passage, but Bexell et al. recently showed that sphere 
formation is not prerequisite for enrichment of CSCs, and pointed out that glioma cells 
growing as monolayers are also tumorigenic (Bexell et al., 2009), like in the case of neural 
stem cells that can be maintained in monolayer cultures (Johe et al., 1996). In addition, it is 
virtually impossible to form spheres of CSC that have arisen from a tissue in which the 
condition of sphere assay is unestablished for normal stem cells, and even if spheres are 
formed, it is uncertain if they have significance for stem cell activity in the tissues. Therefore, 
we must note that sphere formation assay has limited utility for isolation of some types of 
CSCs. 
Hoechst 33342 dye effluxing side population (SP): Hoechst 33342 is a fluorescent dye that 
binds to the AT-rich regions of DNA, and most cells are stained with this dye. In most cases, 
stem cells are not stained due to the high expression of ABC transporter family genes to 
efflux this dye. Human fetal neural stem/progenitor cells express high levels of multidrug 
resistance 1 (MDR1, also known as ABCB1, P-gp) gene and ATP-binding cassette sub-family 
G member 2 (ABCG2, also known as Bcrp), and these transporters have important roles in 
normal physiology on the active efflux of xenobiotics from cell body, protecting cells from 
www.intechopen.com
 Glioma Stem Cells  
 
155 
cytotoxic agents. Cells with the capacity to efflux the dye were first identified in the mouse 
bone marrow (Goodell et al., 1996). After staining with Hoechst 33342 dye and exposure to 
UV laser during FACS, a population is referred to as side population (SP) cells because it 
appears as a “side” relative to the positively stained “main” population (MP) in FACS plots 
(Figure 3). Since this discovery, SP technique is applied to enrich putative stem cells and 
progenitors in a number of normal tissues and malignant tumors, including glioma. SP cells 
preferentially express high levels of stemness genes and are capable of differentiating into 
multiple lineages, and thus are considered to function as stem cells in the original tissues 
and tumors (Dean et al., 2005). Importantly, this method itself may affect the tumorigenic 
potential because Hoechst dye is toxic for cells. Minimally toxic concentrations of Hoechst 
33342 should be also determined in the individual experiments. Rhodamine 123, which is a 
mitochondrial dye reflecting mitochondrial content and kinetics, has been used as a less 
toxic dye, by which quiescent stem cells display a low fluorescence in the flow cytometry 
plots. Human bone marrow hematopoietic stem cells (HSCs) have been demonstrated to be 
isolated by the combination of Hoechst 33342 and Rhodamine 123 (Leemhuis et al., 1996). In 
addition, some investigators have reported that MP cells in human GBM biopsies are also 
tumorigenic in mice, although transplantation of SP cells result in a shorter survival of mice 
than MP (Bleau et al., 2009).  
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Fig. 3. FACS plots expanded by side population analysis (A) and representative images of 
SP (B) and MP (C) cells in the C6 glioma cell line. 
Stem cell surface antigens: Potential CSCs can be identified by striking variety of cell 
surface markers or their combinations; e.g. CD34(+)CD38(−) for AML (Bonnet and Dick, 
1997), CD44(+)CD24(−/low) for breast tumor (Al-Hajj et al., 2003) and CD133(+) for brain 
tumor (Singh et al., 2003). However, these methods based on the surface molecules have 
increased some contradiction. For instance, different stem cell markers identify distinct 
subpopulations of cells in one tumor, in all of which population CSC properties may 
sometimes confirmed. In melanoma, at least four subpopulations, CD20(+), CD133(+), BrdU 
label-retaining cells, and SP cells has been separately identified, all of which possess stem 
cell features (Zabierowski and Herlyn, 2008). This diversity of CSC markers suggests that 
one population isolated by certain surface molecules is still heterogeneous, and that 
complete enrichment of CSCs has not been achieved at least in some particular tumor types. 
Furthermore, the frequency of CSCs is highly variable even among the same type of tumors. 
In colorectal tumors, the frequency of tumor initiating cells assessed in NOD/SCID mice 
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broadly ranges from 1.8 to 24.5% (O'Brien et al., 2007), pointing out the requirement for 
more refined markers (or their combinations) and assay systems. Nevertheless, it is evident 
that these surface markers and their roles are important keys to unveil the regulatory 
pathway to maintain CSCs. Actually, in many studies on human brain tumors, GSCs are 
isolated by the elevated expression of CD133, and the CD133(+) subpopulation has the 
higher ability than the other populations to regenerate the original tumors in 
immunodeficient mice (Singh et al., 2004). 
ALDEFLUOR (aldehyde dehydrogenase activity): Measurement of ALDH activity is a 
recent approach for isolation of putative CSCs. The main function of ALDH enzyme is the 
oxidation of intracellular aldehydes. Several isoforms of ALDH family are identified in 
human, and ALDH1 is the primary isoform isolated from human hematopoietic progenitors. 
Recent studies have shown that human and murine hematopoietic progenitors can be 
isolated using the bodipy-aminoacetaldehyde (BAAA, commercially available in a diethyl 
acetate form as ALDEFLUOR), a fluorescent labeled substrate specific for ALDH activity 
(Ginestier et al., 2007). ALDH1 has a role in early differentiation of hematopoietic stem cells 
(HSCs) through conversion of retinol to retinoic acid (Chute et al., 2006). Increased ALDH 
activity is also found in normal neural stem cells and CSC in acute myeloid leukemia (AML) 
(Pearce et al., 2005) and breast carcinomas (Korkaya et al., 2008). 
Xenotransplantation into immunodeficient mice: The first evidence of CSCs was obtained 
by transplantation experiments in the severe combined immunodeficient (SCID) mouse 
(Lapidot et al., 1994), and it was later re-demonstrated in the nonobese diabetic 
(NOD)/SCID mouse (Bonnet and Dick, 1997). However, the use of NOD/SCID mice, which 
T cells and B cells are lacked, has the risk to underestimate the frequency of tumorigenic 
human cancer cells due to the immune response of natural killer cells against the xenobiotic 
cells. Actually, the percentage of melanoma stem cells that form tumors in NOD/SCID/ 
interleukin-2 receptor Ǆ chain (IL2RǄ)-null (NOG) mice, which lack not only T and B but 
natural killer cells, is higher than that in NOD/SCID mice; one in 1000 melanoma cells form 
tumors in NOD/SCID mice, but 1 in 4 can form tumors in NOG mice (Quintana et al, 2008), 
suggesting that the reported frequency of CSCs should be reevaluated in some cancers by 
using the more highly immunocompromised model. Thus current gold standard assay for 
testing whether each cell population fulfils the criteria of CSC (self-renewal, differentiation 
and tumorigenicity) is the orthotopic xenograft experiment where cells are transplanted at 
limiting dilutions into NOD/Shi-scid/IL2RǄ-null (NOG) mice and the frequency of CSCs is 
determined. Especially, serial transplantation into NOG mice is regarded as the best 
functional assay for testing the long-term self-renewal capacity. However, even the use of 
NOG mouse might underestimate the frequency of CSCs due to different tissue 
environment between mouse and human. If mouse ligands such as growth factors and 
adhesion molecules do not have the compatibility with human receptors, tumorigenic 
human cells might lose the ability to proliferate and survive in mice. Also, even being 
compatible, rodent normal tissues could not precisely recapitulate the patients’ tumor 
microenvironment. Therefore, the challenges to establish humanized mouse models in 
which human microenvironment is recapitulated in an animal are recently highlighted.     
2.4 Clinical implications of cancer stem cell 
CSC model has important implications for clinical treatment of tumors, because some 
features of CSCs make them particularly difficult to kill. CSCs reside in relatively quiescent 
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state on cell cycle referred as in the state of “dormancy” and this allows them to evade from 
typical chemotherapeutic regimens that target actively proliferating cells. Many 
investigators attempt to kill tumor cells independently of the cell cycle state or to selectively 
prompt them to enter the cycling state. Moreover, CSCs express the high level of multidrug 
resistant proteins and transporters associated with detoxification, and they are consequently 
conferred multidrug resistance by expelling chemotherapeutic reagents (Dean et al., 2005). 
In addition, CSCs are frequently resistant to standard radiotherapy regimens owing to their 
elevated expression of reactive oxygen species (ROS) scavenging (Diehn et al., 2009) and 
DNA damage response (Bao et al., 2006) genes. Unexpectedly, conventional 
chemo/radiotherapy eventuates in an increased proportion of CSC fraction and in rapid 
relapse of original tumor. Long-term treatment of PTEN-/- neurospheres isolated from 
PDGF-induced gliomas with temozolomide, a standard therapy for GBM patients, induces 
an increase in the amount of SP cells (Bleau et al., 2009). An effective therapeutic approach 
to CSCs enhancing the sensitivity of chemotherapeutic drugs and radiation is therefore 
imperative to develop. 
2.5 Origin of cancer initiating cell 
The revival of CSC concept triggers a debate on whether cancer origin is stem cells or 
terminally differentiated cells. Since 1970s, a large corpus of studies on direct introduction of 
viral oncogenes and mutated genes isolated from patients’ tumors has demonstrated that 
most of normal cells are susceptible to genetic mutations leading to neoplastic 
transformation for the initiation and expansion of tumors. In addition to these findings, the 
observation that a large proportion of tumor cells retain the features of the surrounding 
differentiated epithelium has assured our common interpretation that oncogenic gene 
mutations occur in terminally differentiated cells. However, there are several controversial 
examples that are still difficult to explain standing on this concept for tumor cell origin. For 
example, malignant tumors histologically contain some degree of undifferentiated 
components, but differentiation of cells had been regarded as a unidirectional process under 
normal physiological conditions, and nuclear reprogramming had remained to be clarified 
until recent achievement of nuclear transfer, ES cell-fusion, or creating the induced 
pluripotent stem (iPS) cells (Yamanaka and Blau, 2010). In addition, terminally 
differentiated cells cannot normally divide to proliferate in vivo and thus the possibility is 
low that such sleeping cells have in sequence the opportunities to acquire oncogenic gene 
mutations, although they often undergo spontaneous immortalization in vitro and 
proliferate infinitely as cell lines. In fact, cancers prone to occur in specific tissues with the 
high rate of turnover in cell division, such as skin and gut but not heart. It is conceivable 
that this is a consequence of genetic instability during the frequent divisions of stem cells. 
3. Glioma stem cell 
3.1 Discovery and isolation 
Subsequent to the identification in human AML and breast tumor, CSCs in human glioma 
i.e. glioma stem cells (GSCs) were initially identified in 2004 according to the cell surface 
expression of CD133 protein (Singh et al., 2004). CD133 is one of two members of pentaspan 
transmembrane glycoprotein prominin family and a human homolog of originally isolated 
mouse PROM1 selectively localizing at the apical surface of murine neuroepithelial stem 
cells (Weigmann et al., 1997) and HSCs from human fetal liver, bone marrow and cord 
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blood (Yin et al., 1997). Notably, 100 CD133(+) cells recapitulated the original tumor 
identical to original patients’ tumors in histopathological features, whereas 100,000 
CD133(−) cells could not form any tumors in NOD/SCID mouse brains (Singh et al., 2004). 
Therefore, it was postulated that like normal neural stem-cells (NSCs), stem-like glioma cells 
may compose a glioma hierarchy upon differentiation and that their differentiation lineages 
determine tumor subtypes, i.e. astrocytomas or oligodendrogliomas. On the same year, 
Kondo et al. also succeeded in concentrating GSCs as stem-like SP cells from a rat C6 glioma 
cell line (Kondo et al., 2004). Since these discoveries, many investigators have confirmed the 
major utility of CD133, SP technique, and others for GSCs isolation (Table 1).  
 
Parameters Details of assay ObservedGSC phenotypes References
Neurosphere culture Culturing in serum-free media containing EGF and bFGF
self-renewal
differentiation
tumor formation
Singh et al. 2003
CD133 (AC133 antigen) Magnetic sorting or flow cytometry sorting by CD133 expression
self-renewal
differentiation
tumor formation
Singh et al. 2004 
Side population Staining and flow cytometry sorting based on Hoechst 33342 dye
efflux
self-renewal
differentiation
tumor formation
Kondo et al. 2004
A2B5 antigen Flow cytometry sorting by the expression of a glial progenitor
marker A2B5 tumor formation Ogden et al. 2008
SSEA-1 Flow cytometry sorting by the expression of an embryonic
marker SSEA-1 (stage-specific embryonic antigen 1)
self-renewal
differentiation
tumor formation
Son et al. 2009
Laminin-coated flask Culturing in serum-free media containing EGF and bFGF onlaminin-coated flask
self-renewal
differentiation
tumor formation
Pollard et al. 2009
Integrin alpha 6 Magnetic sorting or flow cytometry sorting by integrin alpha 6
expression alone or in combination with CD133 expression
self-renewal
tumor formation Lathia et al. 2010
Autofluorescence Flow cytometry sorting by intrinsic autofluorescence emission
around 520 nm upon laser excitation at 488 nm
self-renewal
differentiation
tumor formation
Clement et al. 2010
 
Table 1. Cell surface markers and functional assays for the isolation of glioma stem cells 
However, these methods indeed produce some contradictory. First, accumulating reports 
have demonstrated the presence of CD133(-) GSCs (Ogden et al., 2008). Some of fresh GBM 
specimens and commonly used glioma cell lines do not express CD133, but nevertheless 
they can form tumors in vivo (Beier et al., 2007). Second, CD133(+) population in human 
gliomas are generally found at a very low frequency in flow cytometry and sometimes 
barely detectable, which lead to the concept that CSCs are a rare subpopulation in solid 
tumors, but immunohistochemical analysis by several groups and us have demonstrated 
that some of human GBMs contain high CD133(+) fractions (Figure 4B). This discrepancy 
has been thought to be partially caused by the limitation of FACS analysis; i.e. trypsin 
digestion during preparation of cell suspensions is predicted to cleave the 865-amino acids 
long-CD133 sequences at 79 different sites. And many of cleavage sites by trypsin are within 
the glycosylated extracellular loops containing AC133 or AC141 epitopes, although the 
majority of studies on CD133 have ever made use of antibodies against AC133 or AC141 
glycosylated epitopes. Third, CD133 expression was found to be retained in differentiated 
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cancer cells when a glucosylation-independent CD133 antibody was used (Florek et al., 
2005). Other studies also have demonstrated that the expression of AC133 and AC141 
epitopes is down-regulated independently of CD133 mRNA (Corbeil et al., 2000), and that 
the distribution of CD133 mRNA in adult tissues is much wider than that of 
immunoreactivity to the AC133 epitope (Miraglia et al., 1997). Furthermore, human CD133 
transcripts have alternatively spliced variants devoid of AC133 or AC141 epitopes (Fargeas 
et al., 2007), and cytoplasmic localization of CD133 is also observed in human glioma 
sections (Sakariassen et al., 2007). In addition, we also found in human GBM sections the 
broadly ranged frequency of CD133(+) cells using an antibody against C-terminal 
intracellular region of CD133 (Figure 4A and B) and distinct discordance on the expression 
levels between CD133 and another neural stem cell marker Nestin (Figure 4C and D). 
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Fig. 4. (A and B) Different levels of CD133 expression in two human GBM tissues. Each 
tissue was stained with an anti-CD133 antibody. Relatively high frequency of CD133(+) cells 
are observed in B, but rarely detected in A. (C and D) The expression levels of two neural 
stem cell markers CD133 and Nestin does not coincide in the same GBM tissue. A GBM 
tissue was stained with an anti-CD133 (C) and nestin (D) antibody. 
Given these unresolved problems might lead to our underestimation of the size of true 
GSCs, it must be again deliberated whether CD133 could be utilized as a marker for GSC 
isolation. It may be one goal in future studies to find other markers (or their combination 
with CD133) to accurately define GSC population. 
In contrast, SP method can compensate the disadvantage of cell surface marker-dependent 
isolation that fails when stem cell markers are unknown. Subsequently to the study with the 
C6 glioma cell line, SP cells have been detected in not only human glioma cell lines U87MG, 
T98G, U251 and U373, but also two primary gliomas in transgenic mouse models; Ntv-
a/Ink4a−/−Arf−/−PTENflox/flox mice (Bleau et al., 2009) and S100ǃ-verbB:p53−/− mice (Harris 
et al., 2008), which are reported to be more self-renewable and tumorigenic than MP cells 
and able to reconstitute cellular heterogeneity. However, the isolation of SP cells from 
primary human GBMs and relevant correlation between SP and glioma malignancy have 
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been little reported. Interestingly, Pollard and colleagues have proposed a protocol for the 
efficient establishment of GSC lines as culturing on laminin-coated flask, in which GSCs 
could be expanded in adherent culture for at least 1 year (>20 passages) with retaining stem 
cell properties and tumor initiation capacity (Pollard et al., 2009). They pointed out some 
problems on the use of the traditional neurosphere culture in GSCs isolation and 
highthroughput assays i.e. drug screenings. First, they claimed that the efficiency to 
successfully establish GSC lines from primary tumors is very low (from 1 to 30%). Second, 
spheroid cells tend to spontaneously undergo differentiation and apoptosis, and therefore it 
is complicated to identify the precise molecular targets against the true GSCs. Finally, the 
non-adherent aggregates make real-time observation of cellular behaviors more challenging, 
compared to adherent cells. Actually, they provided a proof-of-principle chemical screen 
using a live-cell imaging system to monitor the effects of FDA (Food and Drug 
Administration)-approved 450 compounds for potential anti-GSC activity, and identified 23 
compounds having cytotoxic activity against all tested GSCs. This approach could greatly 
improve the work to probe GSC biology and to identify agents that selectively and directly 
target GSCs. 
3.2 Signalling to regulate GSC (Therapeutic candidate) 
GSC now attracts much attention with expectations that targeting GSCs could induce 
effective eradication of glioma. Currently, remarkable insights have been gained regarding 
intracellular and extracellular signalling pathways that are crucial in GSC malignancies 
(Figure 5), all of which are potential candidates for anti-GSC therapy.   
3.2.1 Membrane-bound receptor-mediated signalling 
Receptor tyrosine kinases (RTKs) 
RTKs are the cell surface receptors for many growth factors, cytokines, and hormones, and 
have been known as not only key regulators of normal cellular processes but also critical 
stimuli in the development of many cancers.  
The most frequent genetic alteration associated with human GBMs is amplification of EGF 
receptor (EGFR) gene, and its overexpression is observed in approximately 50–60% of GBM 
patients. The most common EGFR mutant is EGFRvIII, which is an in frame deletion variant 
that has a truncated extracellular domain with ligand-independent constitutive activity. The 
Ink4a/Arf−/− astrocytes dedifferentiate in response to EGF. Moreover, transduction of 
EGFRvIII into Ink4a/Arf−/− neural stem cells (NSCs)/astrocytes induces tumors displaying a 
common high-grade glioma phenotype (Bachoo et al., 2002). Soeda et al. (2008) have 
demonstrated that human GBM CSCs retain their self-renewal ability in the presence of EGF 
and that the tyrosine kinase inhibitors of EGF signaling, AG1478 and gefitinib suppress the 
proliferation and self-renewal of these cells. Mazzoleni et al. (2010) also have showed that 
EGFR expression is heterogenous in human GBMs and its high expression can identify tumor 
initiating cells. Interestingly, genomic heterogeniety of EGFR gene links to mutual 
communication between tumor cells, in which IL-6 and LIF proteins secreted from EGFRvIII-
expressing GBM cells enhance wild-type EGFR-expressing GBM cell growth (Inda et al., 2010). 
From these data, targeting of EGFR seems reasonable for eradication of GSCs. However, 
despite several inhibitors of EGFR are now available in the glioma clinic, their efficacy is 
limited, suggesting that some combinatorial approach could improve clinical outcome. 
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Fig. 5. Extracellular signaling and intracellular factors regulating glioma stemness. 
PDGF functions in the later period in development as a potent mitogen of oligodendrocyte 
precursor cells (OPCs). OPCs express PDGF receptor (PDGFR), and PDGF is important for 
regulating OPC number and oligodendrocyte production. Additionally, PDGF signaling has 
been closely associated with the formation of glioma. Activation of PDGF pathway has been 
found in more than 80% of human oligodendrogliomas and in 50-100% of human 
astrocytomas. Daii et al. have reported that PDGF-B overexpression causes the proliferation 
of Nestin+ neural progenitors to form human oligodendroglioma-like tumors and also 
induces the dedifferentiation of GFAP(+) astrocyte into glial precursor-like cells (Dai et al., 
2001). Recently, PDGFRǂ-expressing cells in the adult subventricular zone (SVZ) have been 
proposed as adult NSCs, and they are known to exhibit hyperplastic proliferation in 
response to excessive PDGFR activation (Jackson et al., 2006). These data suggest that 
PDGF/PDGFR pathway may contribute to not only glioma progression but also glioma 
initiation originated from immature stem-like cells. 
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RTK signallings are transmitted into nucleus by intracellular molecules, such as Ras/ERK 
and PI3K/Akt. Given that the combined activation of Ras and Akt in nestin(+) neural 
progenitors induces GBM in mice (Holland et al., 2000) and that the activity of drug 
transporter ABCG2 is regulated by PI3K/Akt pathway (Bleau et al., 2009), RTK signalling 
might control multiple behaviors of GSC in glioma progression and therapy-resistance. 
Transforming growth factor-beta (TGF-β) 
TGF-ǃ superfamily proteins play a critical role on morphogenesis and cell lineage 
specification during brain development. In response to TGF-ǃ, Smad2/3 becomes 
phosphorylated and forms a heterodimeric complex with Smad4, and then its complex is 
translocated into the nucleus to transactivate downstream target genes. Bone morphogenetic 
proteins (BMPs) belonging to a subset of the TGF-ǃ superfamily is known to maintain self-
renewal and multi-lineage differentiation potential of NSCs within the SVZ of the adult 
brain. In human GBMs, enhanced expression of the TGF-2 and TGF receptor I/II are 
detected. Two groups have reported that TGF-ǃ enhances human GBM stemness and 
tumorigenic activity; one is through Sox4-mediated Sox2 induction (Ikushima et al., 2009) 
and another is through the induction of LIF secretion in an autocrine/paracrine fashion 
(Peñuelas et al., 2009). Consistent with these data, TGF-ǃ receptor I inhibitor LY2109761 and 
SB431542 decrease the CD44high/Id1high GBM CSCs population through the repression of Id1 
and Id3 levels (Anido et al., 2010). However, TGF-ǃ family proteins can function as both 
oncogenes and tumor suppressors. Lee et al. (2008) have reported that the expression of 
BMP receptor 1B is downregulated in human GBM CSCs through EZH2-dependent 
epigenetic silencing and thereby tumor stemness is maintained with impaired astroglial 
differentiation. Although these opposite roles of TGF-ǃ on differentiation has remained to 
be resolved, these data indicate that TGF-ǃ family proteins and their downstream targets 
have fundamental roles in glioma stemness and suggest that control of them could yield 
glioma eradication. 
Interleukin-6 (IL-6) 
IL-6 family of cytokines stimulate cells by forming the receptor complex composed of the 
each cytokine-specific receptor and the common component gp130 glycoprotein, leading to 
phosphorylation of signal transducers and activators of transcription (STAT3 and, to a less 
extent, STAT1) by gp130-associated janus kinases (JAKs). The phosphorylated STAT3 and 1 
homodimerize and translocate into the nucleus where downstream target genes are 
transactivated. Several reports have shown that GBM tissues contain significantly higher 
levels of IL-6 protein, and higher IL-6 mRNA correlates with poor survival of GBM patients. 
In addition, phosphorylation and nuclear translocation of STAT3 positively correlate with 
the histopathological grade in human glioma samples (Weissenberger et al., 2004). Recent 
papers have demonstrated that targeting of either IL-6 receptor alpha or IL-6 by using 
lentiviral transduced shRNA or IL-6 antibody decrease tumor growth and survival in mice 
bearing intracranially xenografted human glioma (Wang et al., 2009). Likewise, STAT3 
inhbitors (S3I-201 and STA-21) and RNAi-mediated knockdown of STAT3 prevent growth 
of human primary GBM CSCs (Sherry et al., 2009). Leukemia inhibitory factor (LIF), one of 
the cytokines of the IL-6 family which is known to be an essential factor for mouse 
embryonic stem cell self-renewal and maintenance, induces astrocytic differentiation of 
NSCs in cooperation with BMP2. As described above, transactivation of the LIF gene in 
glioma spheres by TGF-ǃ enhances glioma stemness and then results in significantly shorter 
survival in mice when inoculated (Peñuelas et al., 2009). These effects of LIF on GSCs show 
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important contrast to those on NSCs and therefore LIF inhibition might be one potential 
approach whose side-effects are minimized during treatment.        
Sonic hedgehog (Shh), Notch, and Wnt 
Because GSCs share common properties with NSCs, molecular mechanisms underlying self-
renewal and differentiation are usually overlapped among them. The Shh, Notch and Wnt 
pathways play a major role in normal stem cell regulation and also there is much evidence 
that aberration of these pathways cause tumorigenesis.  
Sonic hedgehog binds to the Patched-1 (Ptc1) receptor and in turn activates the transcription 
factors of GLI family by cancelling the Patched-mediated inactivation of Smoothened (Smo). 
Shh signalling regulates neural progenitor proliferation and self-renewal in adult 
cerebellum, and it is well known that deregulation of Shh pathway in cerebellum neural 
progenitors induces medulloblastoma in mouse models. In human GBMs, amplification and 
overexpression of Gli-1 is reported in several types of gliomas. Hsieh et al. (2011) have 
reported that Shh/Gli1 signaling regulates insulin-like growth factor (IGF)-1-dependent 
GSC proliferation and chemo/radioresistance through insulin receptor substrate 1 (IRS1) 
gene transactivation. Xu et al. (2008) have identified Shh-dependent CSCs in some cases of 
human GBMs and found that activity of Shh signaling in PTEN-positive GBMs correlates 
with reduced patients’ survival. 
Notch is a membrane-bound receptor, and its intracellular domain is proteolytically released 
by binding of membrane-associated ligands Delta and Jagged and in turn binds to 
promoters of genes encoding bHLH transcription factors. Notch activation is involved in the 
regulation of NSC self-renewal, but it promotes glial differentiation in some conditions. 
Abnormal activation of Notch signaling has been found in a wide range of human cancers, 
including glioma. Fan et al. (2010) have reported that a Ǆ-secretase inhibitor GSI-18, which 
prevents Notch secretion, suppresses neurosphere clonogenicity in vitro and growth of 
intracranial CD133-positive GBM cells through loss of AKT and STAT3 phosphorylation. 
Importantly, the combination of Ǆ-secretase inhibitors and irradiation can attenuate cell 
growth and clonogenic survival of GBM CSCs (Wang et al., 2010a). 
Wnt signaling pathway also controls the size of the NSC population through ǃ-catenin 
activation. Wnt binds to a transmembrane receptors Frizzled (Fzd), leading to the 
phosphorylation of the Dishevelled, which prevents glycogen synthase kinase 3ǃ (GSK3ǃ)-
dependent degradation of ǃ-catenin. ǃ-catenin translocates into the nucleus where it binds 
to TCF/LEF and displaces corepressors to induce expression of target genes. Although Wnt 
is mutated in a subgroup of medulloblastomas, its role in gliomas is little known. Zheng et 
al. (2010) have recently proposed Wnt signaling as promising targets for GBM treatment. 
They identified PLAGL2 as a protooncogene amplified and/or overexpressed in human 
GBMs. Enhanced PLAGL2 expression promotes GSC self-renewal and contributes to 
gliomagenesis. They showed that PLAGL2 modulates the transcription of Wnt6 and Fzd9 
and Fzd2 receptors, but in this paper transcriptome analysis is examined in only p53−/− 
NSCs, and therefore it remains still unclear whether Wnt contributes to the malignant 
behaviors of GSCs. 
L1CAM 
The neural cell adhesion molecule, L1CAM (CD171) regulates neural cell growth, survival, 
migration during brain development. Although the role of L1CAM in the normal adult 
brain is not well defined, L1CAM is overexpressed in human gliomas and associated with 
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invasive phenotype. L1CAM is highly expressed in CD133(+) glioma cells and that its 
knockdown suppresses glioma growth in vivo and increases survival of xenografted mice 
with downregulation of NSC transcription factor Olig2 and upregulation of cyclin-
dependent kinase inhibitor p21WAF1/CIP1 (Bao et al., 2008). These data suggest that L1CAM is 
a functional marker of GSC and its inhibition might be useful as a CSC–directed therapy. 
3.2.2 Nuclear transcriptional factors 
Signals and stresses from outside of the cells are transduced into nucleus, where expression 
of downstream targets is regulated by transcriptional and/or epigenetic factors, and lead to 
a variety of cellular phenotypes. Some nuclear factors are currently suggested to be essential 
for GSC behaviors and most of them regulate the self-renewal and differentiation. 
Myc 
Zheng et al. (2008) have performed wide-scale transcriptome/promoter studies and found 
strong enrichment of Myc binding elements in human primary GBMs. They revealed that 
the increase of Myc expression by the defect of p53 and PTEN in GBM CSCs withstands the 
differentiation and then enhances tumorigenic potential. These results strongly support pro-
differentiation as a potential strategy against GSCs and encourage the identification and 
screening of agents targeting these differentiation pathways.  
Sox11 
Hide et al. (2009) have identified Sox11 as a candidate to induce differentiation in GSCs. 
Sox11 is exclusively overexpressed in non-tumorigenic glioma cells, and overexpression of 
Sox11 inhibits tumorigenesis of GSCs by inducing their neuronal differentiation. Sox11 is 
expressed in the committed neuronal precursor cells but not in NSCs, and negatively 
regulates the expression of PLAGL1, which is expressed in developing neuroepithelial cells. 
Knockdown of PLAGL1 significantly improves overall survival of xenotransplanted mice. 
Considering that PLAGL2 also regulates GSC self-renewal (Zheng et al., 2010), these PLAG 
family genes of transcriptional factors might play essential oncogenic roles. As both 
PLAGL1 and PLAGL2 are known to activate IGF2 promoters, the relevance between PLAG 
genes, Shh, IGF, and Wnt suggest that highly complicated cross-talk of multiple signaling 
regulates GSC features. 
Nkx2.2 
Muraguchi et al. (2011) have recently identified the homeodomain transcription factor 
Nkx2.2 as an inducer of GSCs toward oligodendroglial differentiation by using a 
sophisticated mouse models developing glioma at 100% penetrance. During normal 
development of brain, Nkx2.2 cooperates with Olig2 to promote oligodendrocyte 
maturation. Overexpression of Nkx2.2 inhibits self-renewal of human GSCs by induction of 
oligodendroglial differentiation, and therefore reactivation of Nkx2.2 expression in glioma is 
suggested as a novel therapeutic strategy.  
Nanog 
The puluripotent protein Nanog promotes not only embryonic stem (ES) cell expansion but 
also GSC tumorigenicity. GBMs show ES-like stemness signature that includes the 
expression of Nanog, OCT4, SOX2 and c-Myc (Ben-Porath et al., 2008). Knockdown of 
Nanog1 or Nanog2 suppress tumor growth after orthotopic xenotransplantation of GBM 
spheres and this effect is mediated by a positive-feedback loop of Nanog with Gli-1, and 
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repression of Nanog by p53, which acts in a negative-regulatory loop with Gli-1, suggesting 
functional crosstalk among transcriptional factors in regulating the stem cell behavior and 
glioma growth (Zbinden et al., 2010). 
3.2.3 DNA-damage response (DDR) 
The large-scale genomic analyses have revealed genomic loss of at least one allele of ATR, 
ATM, CHEK1, or CHEK2 in 36% of human GBM samples, which are genes encoding key 
components of DDR required for cell-cycle checkpoint. Approximately 50% of GBM patients 
with CHEK2 alterations carry defects in the p53 signaling pathway (Squatrio et al., 2010). As 
the defect of DNA repair factors leads cells to genomic instability, genomic loss of DDR 
components might contribute to glioma initiation. However, Bao et al. (2008) have reported 
that CD133+ primary GBM cells, not CD133- cells, have high activity of DDR response and 
thereby can repair ionizing radiation-dependent DNA damages. Wang et al., (2010a) 
showed that Notch signaling promotes radioresistance through regulation of the PI3K/Akt 
pathway and myeloid cell leukemia 1 (Mcl-1), but it remains unelucidated why only GSCs 
acquire and/or retain the high activity of DDR response.  
3.2.4 Epigenetic factors 
The DNA-methylation and histone-modification patterns are associated with the 
development and progression of cancers. Hundreds of genes are subject to DNA 
hypermethylation at their CpG island promoters. On the contrary, DNA hypomethylation is 
also detected by locus-specific and genome-wide. Histone modifications are also likely 
important in the pathology of GBM. However, the molecular aspects of them are not yet 
fully determined. One important example of DNA hypermethylation is the silencing of O6-
methylguanine-DNA methyltransferase (MGMT) gene in human GBMs (Hegi et al., 2005). 
MGMT gene encodes a DNA repair protein that removes alkyl at the O6 position of guanine, 
which protect glioma cells from chemotherapeutic alkylating agents, such as temozolomide. 
MGMT hypermethylation has been considered as a predictor of outcome after treatment, 
but it is unrevealed if longer patients survival is directly due to reduced MGMT expression. 
As epigenetic modification can alter the differentiation properties of normal stem cells, some 
epigenetic factors have been examined their roles in GSC maintenance and tumor 
development. 
EZH2 
Enhancer of zeste homologue 2 (EZH2) is a component of the polycomb repressive 
complexes (PRC) 2 that participates in transcriptional repression of specific genes by mainly 
trimethylation of lysine 27 of histone H3. EZH2 is upregulated in a broad range of human 
neoplasms and its overexpression is correlated with poor prognosis. Suvà et al. (2009) have 
reported that pharmacologic depletion of EZH2 by the S-adenosylhomocysteine hydrolase 
inhibitor 3-Deazaneplanocin A (DZNep) reduces the self-renewal and tumor-initiating 
properties of GBM GSCs. Interestingly, their effects are mediated by c-myc downregulation, 
even though EZH2 belongs to a repressive complex. 
Bmi-1 
B lymphoma mouse Moloney leukemia virus insertion region (Bmi)-1 is a component of PRC1 
complex which allows stable silencing of gene expression. PRC1 and PRC2 cooperatively 
modify histone status. Abdouh et al. (2009) have reported that Bmi-1, as well as EZH2, is 
highly enriched in CD133(+) GBM cells and that knockdown of Bmi-1 can deplete the 
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CD133(+) cell population and inhibit intracranial tumor formation. Bmi-1 directly represses 
p21Cip expression. It may also directly repress FOXOA3 expression, a potent inducer of 
apoptosis, and thereby supports cell-cycle progression and survival (Abdouh et al. 2009). 
Polycomb group proteins seem to regulate important aspects of GSC biology. 
3.2.5 microRNA (miRNA) 
microRNAs are non-coding RNAs of 22 nucleotides in length and regulate the translation 
and degradation of mRNAs by base-pairing to untranslated regions (UTRs) of targets. 
Approximately 1000 species of microRNA are thought to exist in the human genome. One 
microRNA has hundreds of targets, and one gene is targeted by multiple microRNAs (Krek 
et al., 2005). Increasing evidence strongly suggest that microRNAs are involved in neural 
development. The most highly expressed microRNAs in brain are miR-124 and miR-128, 
both of which are preferentially expressed in neurons. Some groups have investigated the 
direct roles of miRNAs in GSC features. SMAD3/4-controlled miR-451 expression has been 
shown to increase neurosphere formation of CD133(+) GBM cells (Gal et al., 2008). 
Interestingly, another group has reported that miR-451 regulates the expression of MDR1, 
which links to chemoresistant feature in cancer cells (Zhu et al., 2008). Conversely, the 
expression of miR-124 and miR-137 are significantly reduced in grade III and IV malignant 
gliomas and overexpression of these two microRNAs promotes differentiation of human 
GBM stem cells, indicating their tumor suppressive roles (Silber et al., 2008). miR-128 
targeting to the Bmi-1 gene expression is known to be down-regulated in human GBMs, and 
its restoration specifically blocks proliferation of glioma spheres (Godlewski et al., 2008).  
3.3 GSC niche (Therapeutic strategy) 
As well as normal NSCs, GSCs are believed to be physically situated in the specialized 
microenvironment called “stem cell niche”. Niche cells provide extrinsic cues as described 
above, including soluble factors, membrane-bound ligands, and extracellular matrix (ECM) 
proteins. Cell-to-cell communication between stem cells and the niche regulates self-
renewal, differentiation, and maintenance of proper stem cell numbers and functions. 
Tumor niche is thought to be composed of tumor vascular endothelial cells, stromal 
fibroblasts, and immune cells. Considering that CSCs display enhanced resistance to 
conventional chemotherapies due to their increased expression of membrane pumps, cancer 
treatment should be aimed at not the conventional elimination of the proliferating cancer 
cell population but the disruption of cellular niches to induce stem cell differentiation. The 
stromal components that function as niche would therefore be most promising targets to 
eradicate GSCs (Figure 6).  
Vascular niche 
Enhanced neovascularization is one of the characters of malignant gliomas and it 
significantly correlates with tumor aggressiveness and poor clinical prognosis. An initial 
report on GSC niche was proposed as a perivascular niche, where GSCs closely interact with 
vascular endothelium (Calabrese et al., 2007). It was verified by subsequent studies showing 
that glioma cells express high levels of laminin receptor integrin ǂ6ǃ1 in the perivascular 
niche and CD133(+)/integrinǂ6 (high) glioma cells exhibit stem cell properties (Lathia et al., 
2010). In addition, secreted nitric oxide (NO) from the vascular endothelium regulates 
adjacent Nestin(+) glioma cells (Charles et al., 2010). GSCs are themselves tightly involved 
in tumor angiogenesis. Folkins et al. (2009) have demonstrated that GSCs increase 
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endothelial cell proliferation and tube formation in vitro. In addition, GSCs in xenografted 
mice increase mobilization of bone marrow–derived endothelial progenitor cells and recruit 
them to the tumor through amplified secretion of vascular endothelial growth factor (VEGF) 
and stromal-derived factor 1 (SDF-1, also known as CXCL12). Surprisingly, two groups have 
provided strong evidence that a proportion of the vascular endothelial cells in human GBMs 
are originated from the tumor cell itself, which are differentiated ones from GSCs (Wang et 
al., 2010b; Ricci-Vitiani et al., 2010). DAPT, a Ǆ-secretase inhibitor that effectively inhibits 
Notch signalling was found to induce significant suppression of the transition from 
CD133(+)/CD144(−) GSCs into CD133(+)/CD144(+) endothelial progenitors. In addition, 
bevacizumab, a VEGFA-binding antibody, blocked further maturation from endothelial 
progenitors into CD105(+) endothelial cells. These data suggested again that GSCs are 
critical targets in glioma biology and treatment.  
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Fig. 6. The concept of niche therapy and components of GSC niche.  
Hypoxic niche 
Although the perivascular niche is well accepted, low oxygen areas away from tumor 
vessels are also recognized as secondary niches that play a role in GSC regulation. CD133 
expression increases by approximately two-fold when primary glioma spheres are 
incubated in physiological concentrations of oxygen (7%) (McCord et al., 2009). In addition, 
hypoxia (1%) increases the self-renewal capacity of CD133(+) human GSCs independent of 
PI3K/Akt or ERK pathways (Soeda et al., 2009). The hypoxia-inducible factors (HIFs) are 
transcription factors that help cells to adapt to changes in oxygen concentrations. HIFs have 
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more than 60 putative downstream genes that are involved in angiogenesis, glucose 
transport, glycolysis, cell survival, and metastasis. Li et al. (2009) have reported that 
knockdown of either HIF-1ǂ or HIF-2ǂ in GSCs decreases tumorigenic potential and 
increases the survival of xenografted mice and that elevated HIF-2ǂ expression is correlated 
with poor survival of human glioma patients. Méndez et al. (2010) have also demonstrated 
that HIF-1ǂ plays a role in the survival and self-renewal potential of GSCs. Some 
chemotherapeutic agents which target RTKs, such as gefitinib (Iressa, an inhibitor of 
EGFR/ERBB1) and imatinib (Glivec, an inhibitor of Bcr-Abl and PDGFRǃ), have been 
shown to inhibit HIF-1 activity (Pore et al., 2006; Kimura et al., 2007), and further evidence 
has shown that hypoxia mediates resistance to chemotherapy and radiation (Teicher, 1994). 
The formation of necrosis, which is a resultant of increasing cellularity and poorly organized 
tumor vasculature, is a biologic hallmark in a highly aggressvie gliomas. Therefore, 
understanding of stem cell biology in hypoxic environment could also provide useful clues 
for glioma biology and treatment. 
Cancer-associated fibroblast 
Stromal fibroblasts, which are potentially originated from bone marrow-derived 
mesenchymal stem cells (MSCs), are observed as a cellular component in the tumor 
microenvironment and have important roles in the tumor progression. Especially, during 
tumor-induced angiogenesis, fibroblasts actively contribute to neovascularization through 
secretion of VEGF. They also produce ECM proteins such as fibronectin and type I collagen, 
both of which are involved in the initiation of tumor angiogenesis. Additionally, fibroblast-
derived SDF-1 is responsible for recruiting endothelial progenitor cells into a tumor mass, 
thereby boosting tumor angiogenesis (Orimo et al., 2005). In parallel, the SDF-1 protein 
enhances tumor growth in a direct paracrine fashion via the CXCR4 receptor. Although 
whether stromal fibroblasts could affect GSCs behaviors is not yet so clear, it is worth noting 
that some MSCs are exactly detected as a tumor-stimulating component around the blood 
vessels and closely associated with endothelial cells/pericytes in tumor xenograft models 
(Spaeth et al., 2009). 
Tumor-associated macrophages 
Tumor-associated macrophages (TAMs) represent the major inflammatory component of the 
stroma in many tumors. TAMs are derived from circulating blood monocytes and recruited 
into the tumor region toward monocyte chemotactic protein-1 (MCP-1, also known as CCL2) 
and macrophage colony stimulating factor (M-CSF). TAMs display several pro-tumoral 
functions, including tumor growth (growth factors), neo-angiogenesis (VEGF and PDGF), 
matrix remodeling (MMPs), and anti-tumor immune suppression (prostaglandins, IL-10 and 
TGF-ǃ) (Sica et al., 2006). There is no evidence on the exact roles of TAMs against GSCs, but 
ablation of TAMs might provide some therapeutic benefits against GSCs beyond disrupting 
vascular niche. 
4. Conclusion 
The existence of CSCs has altered our view on glioma biology, which prompts our re-
evaluation of conventional strategies in therapies for glioma. Although some controversy is 
still unresolved regarding the definition, isolation methods, characteristics, and their exact 
roles in vivo, it is assured that gliomas have a cellular hierarchy and that certain 
subpopulation within tumors has extraordinary potential for tumor progression, therapeutic 
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resistance, and tumor recurrence. Importantly, GSCs are highly resistant to 
chemo/radiotherapies, which are convinced by the currently poor record of clinical 
remission with conventional treatments. Therefore the development of novel therapies 
directed against GSCs is our urgent task. Remarkable insights into the molecular 
mechanisms or signaling pathways that are differentially regulated in GSCs and non-GSCs 
have accumulated in virtue of recent advance in this field. In this chapter, we have provided 
several key signaling pathways that are potentially useful for the future development of 
anti-GSC therapeutics, but at this point most of them are still far away from the clinical 
application. As an achievement, anti-vascular niche therapy with a humanized anti-VEGF-A 
monoclonal antibody bevacizumab, has displayed beneficial effects in phase II clinical trials, 
and approved for recurrent GBM patients in 2009. For relapsed or progressed GBMs, tumor 
responses were observed in 22 of 85 patients (26%) treated with bevacizumab alone 
(Friedman et al., 2009). This is the first major advance in glioma treatment over a decade. 
Nonetheless, our goal of glioma eradication has not been achieved. Additional basic and 
translational research must be carried out to exploit this promising concept for clinical 
advantage. 
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specifically attack the cancer cells requires an understanding of the distinct characteristics of those cells.
Additional detailed information is provided on selected signal pathways in CNS tumors.
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